Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial

IMPORTANCE: Cotargeting vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 may produce anticancer activity in refractory metastatic colorectal cancer (mCRC). The clinical benefit of atezolizumab combined with chemotherapy and bevacizumab remains unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Mettu, Niharika B., Ou, Fang-Shu, Zemla, Tyler J., Halfdanarson, Thorvardur R., Lenz, Heinz-Josef, Breakstone, Rimini A., Boland, Patrick M., Crysler, Oxana V., Wu, Christina, Nixon, Andrew B., Bolch, Emily, Niedzwiecki, Donna, Elsing, Alicia, Hurwitz, Herbert I., Fakih, Marwan G., Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857687/
https://www.ncbi.nlm.nih.gov/pubmed/35179586
http://dx.doi.org/10.1001/jamanetworkopen.2021.49040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857687/
https://www.ncbi.nlm.nih.gov/pubmed/35179586
http://dx.doi.org/10.1001/jamanetworkopen.2021.49040

Ejemplares similares